Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer — Stella

Recruiting

Back to Ovarian Neoplasms trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Israel

Sheba Medical center, Ramat Gan

Key details

Phase

Safety & dosing

Sponsor

Sheba Medical Center

Enrollment target

~24 participants

Started

April 2021

Primary completion

November 2023

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Sex

Female only

Last updated June 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov